Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease

Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association


Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) model for seven therapeutics: aducanumab, crenezumab, solanezumab, bapineuzumab, elenbecestat, verubecestat, and semagacestat.


Kumpal Madrasi, Raibatak Das, Hafiz Mohmmadabdul, Lin Lin, Bradley T. Hyman, Douglas A. Lauffenburger, Mark W. Albers, Robert A. Rissman, John M. Burke, Joshua F. Apgar, Lucia Wille, Lore Gruenbaum, Fei Hua (2021)

Leave site to read publication >>